B. Djulbegovic
Statistics and Probability · 2003–2017
A researcher in the Science corpus: 15 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Statistics and Probability — 60 citations into it
Whom B. Djulbegovic trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts B. Djulbegovic overall
Papers from B. Djulbegovic's perspective
Ordered by how strongly the researchers B. Djulbegovic trusts endorse each paper. Same corpus, a different order for every researcher.
- GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. (Journal of Clinical Epidemiology)
- GRADE guidelines: 2. Framing the question and deciding on important outcomes. (Journal of Clinical Epidemiology)
- Selective publication of antidepressant trials and its influence on apparent efficacy. (New England Journal of Medicine)
- Pharmaceutical industry sponsorship and research outcome and quality: systematic review (British medical journal)
- Assessing Risk of Bias in Included Studies
- Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications (British medical journal)
- Randomized trials stopped early for benefit: a systematic review. (Journal of the American Medical Association (JAMA))
- Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin (Diabetes Care)
- Publication bias in clinical trials due to statistical significance or direction of trial results. (Cochrane Database of Systematic Reviews)
- Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study (British medical journal)
Their papers
- GRADE guidelines: 5. Rating the quality of evidence--publication bias. (2011) — 1,582 citations
- Pharmaceutical industry sponsorship and research outcome and quality: systematic review (2003) — 2,059 citations
- GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). (2011) — 2,570 citations
- GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. (2013) — 694 citations
- Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. (2010) — 602 citations
- GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. (2013) — 862 citations
- Progress in evidence-based medicine: a quarter century on. (2017) — 804 citations
- Platelet Transfusion: A Clinical Practice Guideline From the AABB (2015) — 882 citations
- Research: increasing value, reducing waste 1 How to increase value and reduce waste when research priorities are set (2014) — 1,270 citations
- Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB* (2012) — 1,083 citations
- Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. (2009) — 853 citations
- Recommendations on the Use of 18F-FDG PET in Oncology (2008) — 1,016 citations
- Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. (2008) — 755 citations
- Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. (2006) — 734 citations
- Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) — 2,345 citations